Stephen S. Galliker

Filings by Stephen S. Galliker span 3 companies, the busiest being SELLAS Life Sciences Group, Inc., Osteotech Inc and Dyax Corp. In total, 18 filings cover trades dated from 19 May 2006 to 10 October 2017.

In open-market terms, that means 1 purchase worth €26k on one side and 2 sales worth €991k on the other. Netting one side against the other leaves €965k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 5 share grants and 9 option exercises.

On 10 October 2017 came the latest disclosure, a share grant for €4,443 in SELLAS Life Sciences Group, Inc. The clock since the last published purchase (22 May 2006) now reads 7,460 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.